Literature DB >> 16047124

Atropine for exercise testing after acute myocardial infarction.

Eliana Reyes.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16047124     DOI: 10.1007/s10554-005-3213-8

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


× No keyword cloud information.
  22 in total

1.  Effect of an additional atropine injection during dobutamine infusion for myocardial SPET.

Authors:  B Caner; A Karanfil; U Uysal; L Tokgozoglu; S Aksoyek; O Ugur; I Ciftci; E Atalar; S Kes; C Bekdik
Journal:  Nucl Med Commun       Date:  1997-06       Impact factor: 1.690

2.  Predischarge maximal exercise test identifies risk for cardiac death in patients with acute myocardial infarction.

Authors:  J R Nielsen; H Mickley; E M Damsgaard; A Frøland
Journal:  Am J Cardiol       Date:  1990-01-15       Impact factor: 2.778

3.  Comparison of myocardial blood flow during dobutamine-atropine infusion with that after dipyridamole administration in normal men.

Authors:  E Tadamura; H Iida; K Matsumoto; M Mamede; S Kubo; H Toyoda; T Shiozaki; T Mukai; Y Magata; J Konishi
Journal:  J Am Coll Cardiol       Date:  2001-01       Impact factor: 24.094

Review 4.  Application of meta-analysis using an electronic spread sheet to exercise testing in patients after myocardial infarction.

Authors:  V F Froelicher; S Perdue; W Pewen; M Risch
Journal:  Am J Med       Date:  1987-12       Impact factor: 4.965

5.  Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). DANish trial in Acute Myocardial Infarction.

Authors:  J K Madsen; P Grande; K Saunamäki; P Thayssen; E Kassis; U Eriksen; K Rasmussen; S Haunsø; T T Nielsen; T Haghfelt; P Fritz-Hansen; E Hjelms; P K Paulsen; P Alstrup; H Arendrup; U Niebuhr-Jørgensen; L I Andersen
Journal:  Circulation       Date:  1997-08-05       Impact factor: 29.690

6.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction).

Authors:  Elliott M. Antman; Daniel T. Anbe; Paul Wayne Armstrong; Eric R. Bates; Lee A. Green; Mary Hand; Judith S. Hochman; Harlan M. Krumholz; Frederick G. Kushner; Gervasio A. Lamas; Charles J. Mullany; Joseph P. Ornato; David L. Pearle; Michael A. Sloan; Sidney C. Smith; Joseph S. Alpert; Jeffrey L. Anderson; David P. Faxon; Valentin Fuster; Raymond J. Gibbons; Gabriel Gregoratos; Jonathan L. Halperin; Loren F. Hiratzka; Sharon Ann Hunt; Alice K. Jacobs; Joseph P. Ornato
Journal:  J Am Coll Cardiol       Date:  2004-08-04       Impact factor: 24.094

7.  Atropine increases the accuracy of dobutamine stress echocardiography in patients taking beta-blockers.

Authors:  P M Fioretti; D Poldermans; A Salustri; T Forster; P Bellotti; E Boersma; A J McNeill; E S el-Said; J R Roelandt
Journal:  Eur Heart J       Date:  1994-03       Impact factor: 29.983

8.  Use of atropine in patients with submaximal heart rate during exercise myocardial perfusion SPECT.

Authors:  Andrea De Lorenzo; James Foerster; Maria G Sciammarella; Cathy Suey; Sean W Hayes; John D Friedman; Daniel S Berman
Journal:  J Nucl Cardiol       Date:  2003 Jan-Feb       Impact factor: 5.952

9.  Prognostic significance of impairment of heart rate response to exercise: impact of left ventricular function and myocardial ischemia.

Authors:  Abdou Elhendy; Douglas W Mahoney; Bijoy K Khandheria; Kelli Burger; Patricia A Pellikka
Journal:  J Am Coll Cardiol       Date:  2003-09-03       Impact factor: 24.094

10.  Use of atropine in patients with chronotropic incompetence and poor exercise capacity during treadmill stress testing.

Authors:  Vijaya K Munagala; Vamshidhar Guduguntla; Babak Kasravi; Glenn Cummings; Julius M Gardin
Journal:  Am Heart J       Date:  2003-06       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.